

Alfonso Dueas-Gonzalez

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3811316/alfonso-duenas-gonzalez-publications-by-citations.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

144 papers	4,831 citations	37 h-index	65 g-index
147 ext. papers	5,376 ext. citations	5.1 avg, IF	5.25 L-index

#	Paper	IF	Citations
144	Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1678-85	2.2	324
143	Planning cancer control in Latin America and the Caribbean. <i>Lancet Oncology, The</i> , 2013 , 14, 391-436	21.7	299
142	Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. <i>Cancer Treatment Reviews</i> , 2008 , 34, 206-22	14.4	252
141	A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. <i>Annals of Oncology</i> , 2007 , 18, 1529-38	10.3	177
140	Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy. <i>Clinical Cancer Research</i> , 2003 , 9, 1596-603	12.9	146
139	Epigenetics of cervical cancer. An overview and therapeutic perspectives. <i>Molecular Cancer</i> , 2005 , 4, 38	42.1	142
138	A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care. <i>Oncotarget</i> , 2013 , 4, 502-30	3.3	131
137	Ether a go-go potassium channels as human cervical cancer markers. <i>Cancer Research</i> , 2004 , 64, 6996-7001	10.1	119
136	A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes. <i>BMC Cancer</i> , 2005 , 5, 44	4.8	112
135	A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer. <i>PLoS ONE</i> , 2006 , 1, e98	3.7	109
134	Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer. <i>Cancer Treatment Reviews</i> , 2006 , 32, 180-90	14.4	106
133	Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study. <i>Molecular Cancer</i> , 2005 , 4, 22	42.1	103
132	Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines. <i>Cancer Cell International</i> , 2006 , 6, 2	6.4	101
131	A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results. <i>Medical Oncology</i> , 2011 , 28 Suppl 1, S540-6	3.7	97
130	Molecular modeling and molecular dynamics studies of hydralazine with human DNA methyltransferase 1. <i>ChemMedChem</i> , 2009 , 4, 792-9	3.7	94
129	Cancer progression mediated by horizontal gene transfer in an in vivo model. <i>PLoS ONE</i> , 2012 , 7, e52754	3.7	76
128	Modern management of locally advanced cervical carcinoma. <i>Cancer Treatment Reviews</i> , 2003 , 29, 389-99	14.4	75

127	A phase II study of multimodality treatment for locally advanced cervical cancer: neoadjuvant carboplatin and paclitaxel followed by radical hysterectomy and adjuvant cisplatin chemoradiation. <i>Annals of Oncology</i> , 2003 , 14, 1278-84	10.3	75
126	Global DNA hypermethylation-associated cancer chemotherapy resistance and its reversion with the demethylating agent hydralazine. <i>Journal of Translational Medicine</i> , 2006 , 4, 32	8.5	66
125	The prince and the pauper. A tale of anticancer targeted agents. <i>Molecular Cancer</i> , 2008 , 7, 82	42.1	63
124	Pathologic response and toxicity assessment of chemoradiotherapy with cisplatin versus cisplatin plus gemcitabine in cervical cancer: a randomized Phase II study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005 , 61, 817-23	4	60
123	Radiosensitizers in cervical cancer. Cisplatin and beyond. <i>Radiation Oncology</i> , 2006 , 1, 15	4.2	59
122	Second hit in cervical carcinogenesis process: involvement of wnt/beta catenin pathway. <i>International Archive of Medicine</i> , 2008 , 1, 10		56
121	Orlistat as a FASN inhibitor and multitargeted agent for cancer therapy. <i>Expert Opinion on Investigational Drugs</i> , 2018 , 27, 475-489	5.9	55
120	Brachytherapy versus radical hysterectomy after external beam chemoradiation with gemcitabine plus cisplatin: a randomized, phase III study in IB2-IIB cervical cancer patients. <i>Annals of Oncology</i> , 2013 , 24, 2043-7	10.3	54
119	Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial. <i>Annals of Hematology</i> , 2011 , 90, 379-87	3	52
118	Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acid. <i>Journal of Translational Medicine</i> , 2006 , 4, 55	8.5	51
117	The epigenetic origin of aneuploidy. <i>Current Genomics</i> , 2008 , 9, 43-50	2.6	50
116	Circulating nucleosomes and response to chemotherapy: an in vitro, in vivo and clinical study on cervical cancer patients. <i>International Journal of Cancer</i> , 2003 , 104, 663-8	7.5	49
115	A phase II study of gemcitabine and cisplatin combination as induction chemotherapy for untreated locally advanced cervical carcinoma. <i>Annals of Oncology</i> , 2001 , 12, 541-7	10.3	49
114	Distribution of HPV16 and 18 intratypic variants in normal cytology, intraepithelial lesions, and cervical cancer in a Mexican population. <i>Gynecologic Oncology</i> , 2006 , 102, 230-5	4.9	48
113	The effects of DNA methylation and histone deacetylase inhibitors on human papillomavirus early gene expression in cervical cancer, an in vitro and clinical study. <i>Virology Journal</i> , 2007 , 4, 18	6.1	47
112	Hydralazine-valproate: a repositioned drug combination for the epigenetic therapy of cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014 , 10, 1433-44	5.5	44
111	The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug. <i>American Journal of Cancer Research</i> , 2018 , 8, 317-331	4.4	44
110	Discovery and development of DNA methyltransferase inhibitors using in silico approaches. <i>Drug Discovery Today</i> , 2015 , 20, 569-77	8.8	41

109	Concomitant chemoradiation versus neoadjuvant chemotherapy in locally advanced cervical carcinoma: results from two consecutive phase II studies. <i>Annals of Oncology</i> , 2002 , 13, 1212-9	10.3	37
108	Misoprostol prophylaxis for high-dose chemotherapy-induced mucositis: a randomized double-blind study. <i>Bone Marrow Transplantation</i> , 1996 , 17, 809-12	4.4	37
107	Global strategies for the treatment of early-stage and advanced cervical cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2016 , 28, 11-7	2.4	36
106	DNA methylation-independent reversion of gemcitabine resistance by hydralazine in cervical cancer cells. <i>PLoS ONE</i> , 2012 , 7, e29181	3.7	35
105	Gemcitabine activity in cervical cancer cell lines. <i>Cancer Chemotherapy and Pharmacology</i> , 2001 , 48, 488-92	3.5	34
104	New molecular targets against cervical cancer. <i>International Journal of Women's Health</i> , 2014 , 6, 1023-31	2.8	33
103	Ribavirin as a tri-targeted antitumor repositioned drug. <i>Oncology Reports</i> , 2015 , 33, 2384-92	3.5	31
102	Differential splicing of E6 within human papillomavirus type 18 variants and functional consequences. <i>Journal of General Virology</i> , 2005 , 86, 2459-2468	4.9	31
101	Ivermectin as an inhibitor of cancer stem-like cells. <i>Molecular Medicine Reports</i> , 2018 , 17, 3397-3403	2.9	30
100	Lack in efficacy for imatinib mesylate as second-line treatment of recurrent or metastatic cervical cancer expressing platelet-derived growth factor receptor alpha. <i>International Journal of Gynecological Cancer</i> , 2009 , 19, 1632-7	3.5	30
99	Expression of platelet derived growth factor family members and the potential role of imatinib mesylate for cervical cancer. <i>Cancer Cell International</i> , 2006 , 6, 22	6.4	29
98	Prognostic significance of pathological response after neoadjuvant chemotherapy or chemoradiation for locally advanced cervical carcinoma. <i>International Seminars in Surgical Oncology</i> , 2006 , 3, 3		28
97	Efficacy in high burden locally advanced cervical cancer with concurrent gemcitabine and cisplatin chemoradiotherapy plus adjuvant gemcitabine and cisplatin: prognostic and predictive factors and the impact of disease stage on outcomes from a prospective randomized phase III trial. <i>Gynecologic Oncology</i> , 2012 , 126, 334-40	4.9	27
96	Upregulation of NKG2D ligands and enhanced natural killer cell cytotoxicity by hydralazine and valproate. <i>International Journal of Oncology</i> , 2011 , 39, 1491-9	4.4	27
95	Epigenetic therapy with hydralazine and magnesium valproate reverses imatinib resistance in patients with chronic myeloid leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012 , 12, 207-12	2	26
94	Routine management of locally advanced cervical cancer with concurrent radiation and cisplatin. Five-year results. <i>BMC Women's Health</i> , 2006 , 6, 3	2.9	26
93	Phase II trial of gemcitabine concurrent with radiation for locally advanced squamous cell carcinoma of the head and neck. <i>Annals of Oncology</i> , 2004 , 15, 301-6	10.3	26
92	A phase I study of carboplatin concurrent with radiation in FIGO stage IIIB cervix uteri carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003 , 56, 1361-5	4	26

91	Can the state of cancer chemotherapy resistance be reverted by epigenetic therapy?. <i>Molecular Cancer</i> , 2006 , 5, 27	42.1	25
90	N-(2-hydroxyphenyl)-2-propylpentanamide, a valproic acid aryl derivative designed in silico with improved anti-proliferative activity in HeLa, rhabdomyosarcoma and breast cancer cells. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2016 , 31, 140-149	5.6	25
89	Epigenetic therapy and cisplatin chemoradiation in FIGO stage IIIB cervical cancer. <i>European Journal of Gynaecological Oncology (discontinued)</i> , 2010 , 31, 386-91	1.6	23
88	Efficacy of hydralazine and valproate in cutaneous T-cell lymphoma, a phase II study. <i>Expert Opinion on Investigational Drugs</i> , 2017 , 26, 481-487	5.9	22
87	The prognostic significance of leukocytosis in cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2007 , 17, 465-70	3.5	22
86	Computational Studies of 1-Hydrazinophthalazine (Hydralazine) as Antineoplastic Agent. Docking Studies on Methyltransferase. <i>Letters in Drug Design and Discovery</i> , 2005 , 2, 282-286	0.8	22
85	Pharmacogenetics and pharmacoepigenetics of gemcitabine. <i>Medical Oncology</i> , 2010 , 27, 1133-43	3.7	21
84	Induction chemotherapy with gemcitabine and oxaliplatin for locally advanced cervical carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2003 , 26, 22-5	2.7	21
83	A pilot study of nimotuzumab plus single agent chemotherapy as second- or third-line treatment or more in patients with recurrent, persistent or metastatic cervical cancer. <i>Cancer Biology and Therapy</i> , 2015 , 16, 684-9	4.6	20
82	Genetic determinants of cancer drug efficacy and toxicity: practical considerations and perspectives. <i>Anti-Cancer Drugs</i> , 2005 , 16, 923-33	2.4	20
81	Transcriptional changes induced by epigenetic therapy with hydralazine and magnesium valproate in cervical carcinoma. <i>Oncology Reports</i> , 2011 , 25, 399-407	3.5	19
80	Antitumor effects of a drug combination targeting glycolysis, glutaminolysis and de novo synthesis of fatty acids. <i>Oncology Reports</i> , 2015 , 34, 1533-42	3.5	18
79	Thiopurine S-methyltransferase gene (TMPT) polymorphisms in a Mexican population of healthy individuals and leukemic patients. <i>Medical Oncology</i> , 2008 , 25, 56-62	3.7	18
78	Determination of 5-methyl-cytosine and cytosine in tumor DNA of cancer patients. <i>Electrophoresis</i> , 2005 , 26, 1057-62	3.6	18
77	Neuroendocrine marker expression in cervical carcinomas of non-small cell type. <i>International Journal of Gynecological Pathology</i> , 2002 , 21, 368-74	3.2	18
76	Analysis of nm23-H1 expression in breast cancer. Correlation with p53 expression and clinicopathologic findings. <i>Cancer Letters</i> , 1996 , 101, 137-42	9.9	17
75	Concurrent chemoradiation with carboplatin for elderly, diabetic and hypertensive patients with locally advanced cervical cancer. <i>European Journal of Gynaecological Oncology (discontinued)</i> , 2008 , 29, 608-12	1.6	17
74	Emerging drugs for the treatment of cervical cancer. <i>Expert Opinion on Emerging Drugs</i> , 2015 , 20, 165-82	3.7	15

73	Weekly topotecan as second- or third-line treatment in patients with recurrent or metastatic cervical cancer. <i>Medical Oncology</i> , 2009 , 26, 210-4	3.7	15
72	Pharmacokinetics of hydralazine, an antihypertensive and DNA-demethylating agent, using controlled-release formulations designed for use in dosing schedules based on the acetylator phenotype. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2011 , 49, 519-24	2	15
71	Clinical presentation and management of uveal melanoma. <i>Molecular and Clinical Oncology</i> , 2016 , 5, 675-687	15	
70	Pharmacotherapy options for locally advanced and advanced cervical cancer. <i>Drugs</i> , 2010 , 70, 403-32	12.1	14
69	Chemoradiation with gemcitabine for cervical cancer in patients with renal failure. <i>Anti-Cancer Drugs</i> , 2004 , 15, 761-6	2.4	14
68	Weekly cisplatin/low-dose gemcitabine combination for advanced and recurrent cervical carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2001 , 24, 201-3	2.7	14
67	Drug Repurposing for Epigenetic Targets Guided by Computational Methods 2016 , 327-357		14
66	Radiosensitization of cervical cancer cells with epigenetic drugs hydralazine and valproate. <i>European Journal of Gynaecological Oncology (discontinued)</i> , 2014 , 35, 140-2	1.6	14
65	Feasibility and antitumor efficacy , of simultaneously targeting glycolysis, glutaminolysis and fatty acid synthesis using lonidamine, 6-diazo-5-oxo-L-norleucine and orlistat in colon cancer. <i>Oncology Letters</i> , 2017 , 13, 1905-1910	2.6	13
64	Nicotinamide sensitizes human breast cancer cells to the cytotoxic effects of radiation and cisplatin. <i>Oncology Reports</i> , 2015 , 33, 721-8	3.5	13
63	Understanding tumor anabolism and patient catabolism in cancer-associated cachexia. <i>American Journal of Cancer Research</i> , 2017 , 7, 1107-1135	4.4	13
62	Genetic selection of volunteers and concomitant dose adjustment leads to comparable hydralazine/valproate exposure. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2014 , 39, 368-75	2.2	12
61	A clinical and biological overview of gastrointestinal stromal tumors. <i>Medical Oncology</i> , 2005 , 22, 1-10	3.7	12
60	Anemia in cervical cancer patients: implications for iron supplementation therapy. <i>Medical Oncology</i> , 2005 , 22, 161-8	3.7	12
59	Antitumor Effects of Systemic DNase I and Proteases in an In Vivo Model. <i>Integrative Cancer Therapies</i> , 2016 , 15, NP35-NP43	3	12
58	Mutational analysis of BRCA1 and BRCA2 genes in Mexican breast cancer patients. <i>European Journal of Gynaecological Oncology (discontinued)</i> , 2009 , 30, 527-30	1.6	12
57	Pharmacodynamics of current and emerging treatments for cervical cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019 , 15, 671-682	5.5	11
56	Encouraging results with the compassionate use of hydralazine/valproate (TRANSCRIPTION) as epigenetic treatment for myelodysplastic syndrome (MDS). <i>Annals of Hematology</i> , 2017 , 96, 1825-1832	3	11

55	Emerging drugs for cervical cancer. <i>Expert Opinion on Emerging Drugs</i> , 2012 , 17, 203-18	3.7	11
54	Acetylator status and N-acetyltransferase 2 gene polymorphisms; phenotype-genotype correlation with the sulfamethazine test. <i>Pharmacogenetics and Genomics</i> , 2011 , 21, 894-901	1.9	11
53	Drug repurposing for cancer therapy, easier said than done. <i>Seminars in Cancer Biology</i> , 2021 , 68, 123-131	2.7	11
52	DNA Methyltransferase Inhibitors for Cancer Therapy 2015 , 265-290		10
51	Polymorphism in exon 4 of TP53 gene associated to HPV 16 and 18 in Mexican women with cervical cancer. <i>Medical Oncology</i> , 2011 , 28, 1507-13	3.7	10
50	Arylamine N-acetyltransferase 2 genotypes in a Mexican population. <i>Genetics and Molecular Research</i> , 2012 , 11, 1082-92	1.2	10
49	Ocular metastases from breast carcinoma. <i>Medical Oncology</i> , 2004 , 21, 217-21	3.7	9
48	Bioavailability of etoposide after oral administration of the solution marketed for intravenous use: therapeutic and pharmacoeconomic perspectives. <i>Archives of Medical Research</i> , 1999 , 30, 212-5	6.6	9
47	Comparison of DNA demethylating and histone deacetylase inhibitors hydralazine-valproate versus vorinostat-decitabine in cutaneous t-cell lymphoma in HUT78 cells. <i>American Journal of Blood Research</i> , 2018 , 8, 5-16	1.6	9
46	Cytotoxic Activity and Structure-Activity Relationship of Triazole-Containing Bis(Aryl Ether) Macrocycles. <i>ChemMedChem</i> , 2018 , 13, 1193-1209	3.7	9
45	The safety of drug treatments for cervical cancer. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 169-80	4.1	8
44	Metabolic tumor volume changes assessed by interval fluorodeoxyglucose positron emission tomography-computed tomography for the prediction of complete response and survival in patients with diffuse large B-cell lymphoma. <i>Oncology Letters</i> , 2018 , 16, 1411-1418	2.6	8
43	The impact of DNA methylation technologies on drug toxicology. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014 , 10, 637-46	5.5	8
42	Radiation-sparing managements for cervical cancer: a developing countries perspective. <i>World Journal of Surgical Oncology</i> , 2006 , 4, 77	3.4	8
41	Perspectives on Drug Repurposing. <i>Current Medicinal Chemistry</i> , 2021 , 28, 2085-2099	4.3	8
40	Antitumor effects of ivermectin at clinically feasible concentrations support its clinical development as a repositioned cancer drug. <i>Cancer Chemotherapy and Pharmacology</i> , 2020 , 85, 1153-1163	3.5	7
39	Developmental DNA methyltransferase inhibitors in the treatment of gynecologic cancers. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 323-38	4	7
38	Response to hydralazine-valproate in a patient with mycosis fungoides. <i>Case Reports in Medicine</i> , 2010 , 2010, 657579	0.7	7

- 37 Neoadjuvant chemotherapy followed by surgery in locally advanced cervical carcinoma. *Journal of Clinical Oncology*, **2002**, 20, 2908-9; author reply 2809-10 2.2 7
- 36 F18-FDG-PET/CT in the evaluation of patients with suspected recurrent or persistent locally advanced cervical carcinoma. *Revista De Investigacion Clinica*, **2011**, 63, 227-35 1.6 7
- 35 Emerging DNA methylation inhibitors for cancer therapy: challenges and prospects. *Expert Review of Precision Medicine and Drug Development*, **2019**, 4, 27-35 1.6 6
- 34 Pharmacokinetic evaluation of gemcitabine hydrochloride for the treatment of cervical cancer. *Expert Opinion on Drug Metabolism and Toxicology*, **2011**, 7, 1601-12 5.5 6
- 33 Treatment of the adenocarcinoma of the esophagogastric junction at a single institution in Mexico. *Annals of Surgical Oncology*, **2007**, 14, 1439-48 3.1 6
- 32 A pilot study of perilymphatic leukocyte cytokine mixture (IRX-2) as neoadjuvant treatment for early stage cervical carcinoma. *International Immunopharmacology*, **2002**, 2, 1007-16 5.8 6
- 31 Therapy-related myelodysplastic syndrome. *Expert Opinion on Drug Safety*, **2015**, 14, 655-65 4.1 5
- 30 Advancing clinical research globally: Cervical cancer research network from Mexico. *Gynecologic Oncology Reports*, **2018**, 25, 90-93 1.3 5
- 29 Exploring disparities in incidence and mortality rates of breast and gynecologic cancers according to the Human Development Index in the Pan-American region. *Public Health*, **2017**, 149, 81-88 4 4
- 28 Viral inhibitors of NKG2D ligands for tumor surveillance. *Expert Opinion on Therapeutic Targets*, **2016**, 20, 1375-1387 6.4 4
- 27 The combination of orlistat, lonidamine and 6-diazo-5-oxo-L-norleucine induces a quiescent energetic phenotype and limits substrate flexibility in colon cancer cells. *Oncology Letters*, **2020**, 20, 3053-3060 3.6 4
- 26 Growth inhibition and transcriptional effects of ribavirin in lymphoma. *Oncology Reports*, **2019**, 42, 1248-1256 3.5 4
- 25 Mild C(sp)-H functionalization of dihydrosanguinarine and dihydrochelerythrine for development of highly cytotoxic derivatives. *European Journal of Medicinal Chemistry*, **2017**, 138, 1-12 6.8 3
- 24 New pharmacotherapy options for cervical cancer. *Expert Opinion on Pharmacotherapy*, **2014**, 15, 51-60 4 3
- 23 Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma. *Therapeutic Advances in Hematology*, **2021**, 12, 2040620721989579 5.7 3
- 22 An identical, complex TP53 mutation arising independently in two unrelated families with diverse cancer profiles: the complexity of interpreting cancer risk in carriers. *Oncogenesis*, **2012**, 1, e1 6.6 2
- 21 Long-term results of paclitaxel in FIGO stage III ovarian carcinoma. *Anti-Cancer Drugs*, **2003**, 14, 347-52 2.4 2
- 20 Multimodal treatment of locally advanced cervical cancer. *Archives of Medical Research*, **2005**, 36, 129-356 6.6 2

19	Follow-up consultations for cervical cancer patients in a Mexican cancer center. Comparison with NCCN guidelines. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014 , 15, 8749-52	1.7	2
18	In vivo rat model to study horizontal tumor progression. <i>Methods in Molecular Biology</i> , 2014 , 1165, 175-85	4	2
17	The role of extracellular DNA (exDNA) in cellular processes. <i>Cancer Biology and Therapy</i> , 2021 , 22, 267-278	4.6	2
16	Mouse Model for Efficient Simultaneous Targeting of Glycolysis, Glutaminolysis, and De Novo Synthesis of Fatty Acids in Colon Cancer. <i>Methods in Molecular Biology</i> , 2021 , 2174, 45-69	1.4	2
15	G80A Single Nucleotide Polymorphism in Reduced Folate Carrier-1 Gene in a Mexican Population and its Impact on Survival in Patients with Acute Lymphoblastic Leukemia. <i>Revista De Investigacion Clinica</i> , 2016 , 68, 154-62	1.6	2
14	Barriers for Pharmaceutical Innovation With Focus in Cancer Drugs, the Case of Mexico. <i>Therapeutic Innovation and Regulatory Science</i> , 2019 , 216847901983901	1.2	1
13	In Vitro Employment of Recombinant Taenia solium Calreticulin as a Novel Strategy Against Breast and Ovarian Cancer Stem-like Cells. <i>Archives of Medical Research</i> , 2020 , 51, 65-75	6.6	1
12	Hereditary diffuse gastric cancer (HDGC). An overview. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021 , 46, 101820	2.4	1
11	Epidemiological Data on the Nutritional Status of Cancer Patients Receiving Treatment with Concomitant Chemoradiotherapy, Radiotherapy or Sequential Chemoradiotherapy to the Abdominopelvic Area. <i>Revista De Investigacion Clinica</i> , 2018 , 70, 117-120	1.6	1
10	Barriers for Pharmaceutical Innovation With Focus in Cancer Drugs, the Case of Mexico. <i>Therapeutic Innovation and Regulatory Science</i> , 2020 , 54, 342-352	1.2	1
9	Pharmacological inhibition of tumor anabolism and host catabolism as a cancer therapy. <i>Scientific Reports</i> , 2021 , 11, 5222	4.9	1
8	Antimetastatic effect of epigenetic drugs, hydralazine and valproic acid, in Ras-transformed NIH 3T3 cells. <i>OncoTargets and Therapy</i> , 2018 , 11, 8823-8833	4.4	1
7	Ivermectin: Potential Repurposing of a Versatile Antiparasitic as a Novel Anticancer		1
6	Correlation of tumor growth index with early treatment response in cervical carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2002 , 21, 57-63		1
5	Adjuvant high-dose chemotherapy supported by peripheral blood stem cell transplantation for high-risk cervical carcinoma. <i>International Journal of Gynecological Cancer</i> , 1999 , 9, 333-336	3.5	0
4	IMMUNOTHERAPY TREATMENT AGAINST CERVICAL CANCER. <i>Revista De Investigacion Clinica</i> , 2020 , 72, 231-238	1.6	0
3	A Cohort Study of the Prognostic Impact of Exon-16 EZH2 Mutations in a Mexican-Mestizo Population of Patients with Diffuse Large B-Cell Lymphoma. <i>Revista De Investigacion Clinica</i> , 2021 , 73, 362-370	1.6	0
2	Membrane proteins in neoplastic and normal uterine cervix. <i>Journal of Experimental and Clinical Cancer Research</i> , 2001 , 20, 231-7		

- 1 Late recurrence of cervical cancer: a report of 16 cases. *European Journal of Gynaecological Oncology (discontinued)*, **2012**, 33, 485-8 1.6